Identification and Validation of a Novel Antibacterial Compound MZ-01 against Methicillin-Resistant Staphylococcus aureus

Junshu Yang, Christopher Brown, Wayland E Noland, Timothy J. Johnson, Yinduo Ji

Research output: Contribution to journalArticlepeer-review

Abstract

The discovery of new classes of antibiotics is slow, and it is being greatly outpaced by the development of bacterial resistance. This disparity places us in an increasingly vulnerable position because we are running out of safe and effective therapeutic options to treat antibiotic-resistant infections. This is exemplified by the emergence and persistence of hospital-acquired and community-associated methicillin-resistant S. aureus (MRSA), which has markedly narrowed our options for treating life-threatening staph infections. Thus, there is an urgent need to develop novel, potent, preventive, and therapeutic agents. In our current study, we performed a whole-cell screening assay of synthetic libraries for antibacterial activity and identified a novel molecule, MZ-01. MZ-01 exhibited potent bactericidal activity against Gram-positive bacterial pathogens, including MRSA, Streptococcus pyogenes, and Streptococcus pneumoniae, at low concentrations. MZ-01 killed and lysed both the late exponential phase of an S. aureus population and bacteria inside mammalian cells. Furthermore, MZ-01 exhibited low cytotoxicity. These results indicate that MZ-01 is a promising scaffold to guide the development of novel, potent antibacterial agents against multidrug-resistant Gram-positive bacterial pathogens such as MRSA.

Original languageEnglish (US)
Article number1550
JournalAntibiotics
Volume11
Issue number11
DOIs
StatePublished - Nov 2022

Bibliographical note

Funding Information:
This work was supported in part by grant AI078951 (to Y. Ji) from the National Institute of Allergy and Infectious Disease and by a grant from the EZID-Signature Research Program from the College of veterinary medicine at the University of Minnesota USDA General Agricultural Research fund (MIN-63-119 to Y. Ji).

Publisher Copyright:
© 2022 by the authors.

Keywords

  • Gram-positive bacterial pathogen
  • MRSA
  • Staphylococcus aureus
  • antimicrobial agents

Fingerprint

Dive into the research topics of 'Identification and Validation of a Novel Antibacterial Compound MZ-01 against Methicillin-Resistant Staphylococcus aureus'. Together they form a unique fingerprint.

Cite this